Antiarthritic effects of two acyclic
nucleoside phosphonates,
9-(2-phosphonomethoxyethyl)adenine (PMEA;
Adefovir) and
9-(2-phosphonomethoxypropyl)adenine (PMPA), as well as their more bioavailable
prodrugs, bis(pivaloyloxymethyl)
ester of PMEA [
bis(POM)-PMEA;
Adefovir Dipivoxil] and bis(isopropyloxycarbonyloxymethyl)
ester of PMPA [
bis(POC)-PMPA], were investigated in a model of adjuvant-induced
arthritis in Lewis rats. The drugs were injected subcutaneously at doses of 5-50 mg/kg. PMEA and its
prodrug inhibited by > 80% arthritic paw swelling,
splenomegaly and fibroadhesive perisplenitis. Both prophylactic and therapeutic dosing regimens were effective. Neither PMPA nor
bis(POC)-PMPA suppressed development of arthritic lesions. Substantially reduced
nitrite +
nitrate levels were detected in serum and urine of PMEA-treated animals as compared to those of untreated diseased controls. Also, complete suppression of the disease-associated, greatly enhanced systemic levels of the
chemokine,
RANTES (regulated upon activation, normal T cell expressed and secreted), was observed in rats injected with PMEA. Additional in vitro studies showed that PMEA does not change, PMPA enhances, and both
prodrugs inhibit the immune-activated NO production. Under the same conditions PMEA inhibits, while PMPA slightly stimulates, secretion of
RANTES. Collectively, these data suggest that the in vivo-inhibited production of
nitric oxide (NO) is a consequence rather than a mechanism of antiarthritic action of PMEA. Possible mechanisms for the anti-
RANTES activity of PMEA remains to be firmly established.